Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Lymphoma, Follicular 19Lymphoma 19Lymphoma, Mantle-Cell 17Leukemia, Lymphocytic, Chronic, B-Cell 15Lymphoma, Large B-Cell, Diffuse 10Lymphoma, B-Cell, Marginal Zone 10Lymphoma, B-Cell 10Lymphoma, Non-Hodgkin 9Recurrence 6Hodgkin Disease 6Waldenstrom Macroglobulinemia 5Neoplasms 3Multiple Myeloma 3Leukemia 3Burkitt Lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, T-Cell, Peripheral 2Lymphatic Diseases 2Immunoproliferative Disorders 2Immune System Diseases 2Hematologic Diseases 2Sezary Syndrome 1Proteostasis Deficiencies 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Neurotoxicity Syndromes 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1

Interventions

Dexamethasone 17Lenalidomide 15Bortezomib 12Cyclophosphamide 7fludarabine 6carfilzomib 6Melphalan 6daratumumab 5Calcium Dobesilate 5pomalidomide 3gamma-Globulins 3fludarabine phosphate 3belantamab mafodotin 3Whole-Body Irradiation 3Trimethoprim, Sulfamethoxazole Drug Combination 3Tacrolimus 3Mycophenolic Acid 3isatuximab 2elotuzumab 2Sirolimus 2Prednisone 2Immunoglobulins, Intravenous 2Granulocyte Colony-Stimulating Factor 2Etoposide 2Ciprofloxacin 2Amoxicillin-Potassium Clavulanate Combination 2venetoclax 1thymoglobulin 1siltuximab 1poly ICLC 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Plasma Cell × Bendamustine Hydrochloride × 1 year × Clear all
NCT05182073 2025-12-12

FT576 in Subjects With Multiple Myeloma

Fate Therapeutics

Phase 1 Completed
31 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡